These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34065916)

  • 1. Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.
    Tartaglia G; Cao Q; Padron ZM; South AP
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis.
    Rodeck U; Uitto J
    J Invest Dermatol; 2007 Oct; 127(10):2295-6. PubMed ID: 17853916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa.
    Knaup J; Gruber C; Krammer B; Ziegler V; Bauer J; Verwanger T
    Anal Cell Pathol (Amst); 2011; 34(6):339-53. PubMed ID: 22002724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.
    Atanasova VS; Russell RJ; Webster TG; Cao Q; Agarwal P; Lim YZ; Krishnan S; Fuentes I; Guttmann-Gruber C; McGrath JA; Salas-Alanis JC; Fertala A; South AP
    J Invest Dermatol; 2019 Jul; 139(7):1497-1505.e5. PubMed ID: 30684555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression.
    Pourreyron C; Cox G; Mao X; Volz A; Baksh N; Wong T; Fassihi H; Arita K; O'Toole EA; Ocampo-Candiani J; Chen M; Hart IR; Bruckner-Tuderman L; Salas-Alanis JC; McGrath JA; Leigh IM; South AP
    J Invest Dermatol; 2007 Oct; 127(10):2438-44. PubMed ID: 17495952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
    Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
    Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa.
    Ebens CL
    EMBO Mol Med; 2021 Oct; 13(10):e14864. PubMed ID: 34515407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa.
    Primerano A; De Domenico E; Cianfarani F; De Luca N; Floriddia G; Teson M; Cristofoletti C; Cardarelli S; Scaglione GL; Baldini E; Cangelosi D; Uva P; Reinoso Sánchez JF; Roubaty C; Dengjel J; Nyström A; Mastroeni S; Ulisse S; Castiglia D; Odorisio T
    Br J Dermatol; 2024 Sep; 191(4):568-579. PubMed ID: 38820176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
    Santucci C; Alexandru M; Chen X; Mellerio JE; Karagiannis SN; Jacków-Malinowska J
    Hum Immunol; 2024 May; 85(3):110805. PubMed ID: 38703415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial.
    Woodley DT; Hao M; Kwong A; Levian B; Cogan J; Hou Y; Mosallaei D; Kleinman E; Zheng K; Chung C; Kim G; Peng D; Chen M
    Br J Dermatol; 2024 Jul; 191(2):267-274. PubMed ID: 38366625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC.
    Martins VL; Caley MP; Moore K; Szentpetery Z; Marsh ST; Murrell DF; Kim MH; Avari M; McGrath JA; Cerio R; Kivisaari A; Kähäri VM; Hodivala-Dilke K; Brennan CH; Chen M; Marshall JF; O'Toole EA
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development.
    Guerra L; Odorisio T; Zambruno G; Castiglia D
    Matrix Biol; 2017 Nov; 63():1-10. PubMed ID: 28126522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa.
    So JY; Nazaroff J; Iwummadu CV; Harris N; Gorell ES; Fulchand S; Bailey I; McCarthy D; Siprashvili Z; Marinkovich MP; Tang JY; Chiou AS
    Orphanet J Rare Dis; 2022 Oct; 17(1):377. PubMed ID: 36253825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of chronicity signatures in fibroblasts isolated from recessive dystrophic epidermolysis bullosa chronic wound dressings under culture conditions.
    De Gregorio C; Catalán E; Garrido G; Morandé P; Bennett JC; Muñoz C; Cofré G; Huang YL; Cuadra B; Murgas P; Calvo M; Altermatt F; Yubero MJ; Palisson F; South AP; Ezquer M; Fuentes I
    Biol Res; 2023 May; 56(1):23. PubMed ID: 37161592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Collagen VII Replacement Therapy for Advanced Recessive Dystrophic Epidermolysis Bullosa.
    Gretzmeier C; Pin D; Kern JS; Chen M; Woodley DT; Bruckner-Tuderman L; de Souza MP; Nyström A
    J Invest Dermatol; 2022 Apr; 142(4):1094-1102.e3. PubMed ID: 34606885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis.
    Chacón-Solano E; León C; Carretero M; García M; Sánchez-Domínguez R; Quero F; Méndez-Jiménez E; Bonafont J; Ruiz-Mezcua B; Escámez MJ; Larcher F; Del Río M
    Matrix Biol; 2022 Aug; 111():189-206. PubMed ID: 35779740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
    Kim M; Murrell DF
    Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
    Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
    JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of transforming growth factor-β1 in recessive dystrophic epidermolysis bullosa squamous cell carcinoma.
    Twaroski K; Chen W; Pickett-Leonard M; Tolar J
    Exp Dermatol; 2021 May; 30(5):664-675. PubMed ID: 33595864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
    Ng YZ; Pourreyron C; Salas-Alanis JC; Dayal JH; Cepeda-Valdes R; Yan W; Wright S; Chen M; Fine JD; Hogg FJ; McGrath JA; Murrell DF; Leigh IM; Lane EB; South AP
    Cancer Res; 2012 Jul; 72(14):3522-34. PubMed ID: 22564523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.